Efficacy of half-dose verteporfin photodynamic therapy for central serous chorioretinophathy in patients aged above 45

• Main Authors: Yi-Jun Wu, Gen-Gui Xu, Li Mo, Jian-Feng Xu
• Format: Article
• Language: English
• Published: Press of International Journal of Ophthalmology (IJO PRESS) 2017-11-01
• Series: Guoji Yanke Zazhi
• Subjects: central serous chorioretinophathy; photochemotherapy; treatment outcome
• Online Access: http://ies.ijo.cn/cn_publish/2017/11/201711026.pdf
• ISSN: 1672-5123; 1672-5123

AIM: To evaluate the efficacy of half-dose verteporfin photodynamic therapy for central serous chorioretinophathy(CSC)in patients aged above 45 years old. <p>METHODS: Thirty-two eyes of 30 patients aged above 45 years old with central serous chorioretinophathy were included, and all the eyes received half-dose verteporfin photodynamic therapy(PDT). Best-corrected visual acuity(BCVA), central macular thickness(CMT)and subretinal fluids absorption(SRF)were measured before and after treatment(1,3 and 6mo).<p>RESULTS: The rate of SRF absorbing completely was 44% at 1mo, 63% at 3mo and 75% at 6mo. The difference in cure rate of the three time points was statistically significant(<i>χ</i>²=6.621, <i>P</i>=0.037). All the patients were divided into two groups according to the duration, patients in Group A were treated less than 6mo, Group B were ≥6mo. The mean LogMAR BCVA in the two groups were respectively 0.6149±0.4117 and 0.8167±0.4370 before treatment and the mean CMT were 409.47±129.422μm and 395.82±153.756μm before treatment. The difference between the two groups in the LogMAR BCVA was not statistically significant(<i>F</i>=0.303, <i>P</i>=0.823), but the time difference within the subjects was statistically significant(<i>F</i>=32.837,<i>P</i><0.001). In Group A, the differences of the LogMAR BCVA at pre-treatment,1mo and 3mo was all statistically significant(<i>P</i><0.05), but the differences of the LogMAR BCVA at 3mo and 6mo was not statistically significant(<i>t</i>=2.024,<i>P</i>=0.063). In Group B, the differences of the LogMAR BCVA at any two time points were all statistically significant(<i>P</i><0.05). The difference between the two groups in the CMT was not statistically significant(<i>F</i>=0.064,<i>P</i>=0.978), but the time difference within the subjects was statistically significant(<i>F</i>=26.447,<i>P</i><0.001). In Group A,the differences of the CMT at any two time points were all statistically significant(<i>P</i><0.05). So were in Group B(<i>P</i><0.05).<p>CONCLUSION: Half-dose verteporfin PDT was effective in treating CSC aged above 45 years old, it still could improve BCVA and subretinal fluids absorption.